The total return over the past 12 months is +128.66% vs. +16.94% for the S&P 500. So far it's up +41.86% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +128.66% | (10.32%) | (24.23%) | (16.23%) | N/A | N/A |
| Total Return CAGR | +128.66% | (10.32%) | (24.23%) | (16.23%) | N/A | N/A |
| Revenue CAGR | (51.05%) | (35.87%) | +4.39% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Aclaris Therapeutics, Inc. (ACRS)
| Year | Start price | End price | ACRS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.01 | $4.27 | +41.86% | +14.51% | +27.35% |
| 2025 | $2.48 | $3.01 | +21.37% | +17.72% | +3.65% |
| 2024 | $1.05 | $2.48 | +136.19% | +24.89% | +111.30% |
| 2023 | $15.75 | $1.05 | (93.33%) | +26.19% | (119.52%) |
| 2022 | $14.54 | $15.75 | +8.32% | (18.17%) | +26.49% |
| 2021 | $6.47 | $14.54 | +124.73% | +28.74% | +95.99% |
| 2020 | $1.89 | $6.47 | +242.33% | +18.37% | +223.96% |
| 2019 | $7.39 | $1.89 | (74.42%) | +31.22% | (105.64%) |
| 2018 | $24.66 | $7.39 | (70.03%) | (4.56%) | (65.47%) |
| 2017 | $27.14 | $24.66 | (9.14%) | +21.70% | (30.84%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
